Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Leases (Tables)

3 Months Ended

Mar. 31, 2019

During the three months ended March 31, 2019, the Company recorded $0.8 million as lease expense to current period operations.

The following tables summarize quantitative information about the Company’s operating leases, under the adoption of

Topic 842

($ in thousands)	Three Months Ended March 31, 2019
Operating cash flows from operating leases	$	(767	)
Right-of-use assets exchanged for new operating lease liabilities	$	22,618
Weighted-average remaining lease term – operating leases (years)		6.7
Weighted-average discount rate – operating leases		6.2	%

($ in thousands)		Future Lease Liability
Nine months ended December 31, 2019	$	1,871
Year ended December 31, 2020		3,351
Year ended December 31, 2021		3,114
Year ended December 31, 2022		3,084
Year ended December 31, 2023		3,137
Other		23,463
Total operating lease liabilities		38,020
Less: present value discount		(11,550	)
Net operating lease liabilities, short-term and long-term	$	26,470

At December 31, 2018, the total future minimum lease payments under all leases were:

($ in thousands)
2019	$	3,070
2020		3,289
2021		3,084
2022		3,084
2023		3,137
Beyond		23,466
Total minimum lease payments	$	39,130